TP53 alterations and clinical outcome in low grade astrocytomas

✍ Scribed by Jürgen A. Kraus; Carsten Bolln; Helmut K. Wolf; Jürgen Neumann; Dietmar Kindermann; Rolf Fimmers; Frank Forster; Axel Baumann; Uwe Schlegel

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 549 KB
• Volume: 10
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.2870100211

✦ Synopsis

Thirty-eight WHO grade II astrocytomas and I0 malignant recurrent gliomas in these patients were examined for the presence of TP.53 alterations. Seventeed38 low grade astrocytomas and 6/10 malignant recurrent tumors harbored mutations of the gene detected by SSCP analysis and direct sequencing of PCR products. TP.53 mutations in five out of six high grade mutant tumors were already present in the corresponding low grade astrocytomas. In two cases, TP53 mutations present in the low grade astrocytoma could not be demonstrated in the recurrent glioma lmmunohistochemistry with two different antibodies to the human TP53 protein revealed nuclear immunoreaction of tumor cells in I 1/38 low grade and in 8/10 recurrent tumors. There was no correlation between the presence of TP53 alteration and clinical course. We conclude that, although Tf53 mutations are detectable in a substantial fraction of WHO grade II astrocytomas, they do not appear to play a role in the malignant progression of these tumors and they are not of prognostic significance. Genes Chromosom Cancer 10:/43-149 (1994).